Stockscreener 앱 받기
8.81
0.12%
-0.011
시간 외 거래:
8.81
Actuate Therapeutics Inc 주식(ACTU)의 최신 뉴스
Actuate Therapeutics sets annual meeting for May 22 - Investing.com India
Actuate Therapeutics' Lock-Up Period Will Expire on February 10th (NASDAQ:ACTU) - MarketBeat
Actuate Therapeutics to Participate in Upcoming Investor Conferences in February - GlobeNewswire
Ataxia Telangiectasia Market on Track for Major Expansion by 2032, According to DelveInsight | Acasti Pharma Inc., IntraBio Inc - The Globe and Mail
Actuate Therapeutics’ (NASDAQ:ACTU) Lock-Up Period Set To Expire on February 10th - Defense World
Actuate Therapeutics (NASDAQ:ACTU) Trading Down 5.4%Here's What Happened - MarketBeat
Trump 2.0: This Sector May See A Big Performance Boost - The Globe and Mail
Algonquin Power & Utilities Corp. Announces Leadership Transition - The Globe and Mail
Myelofibrosis Clinical Trials, Pipeline Analysis, EMA, PDMA, - openPR
Meta Platforms Is Surging on Q4 Earnings. Is Meta Stock a Buy, Sell, or Hold for 2025? - The Globe and Mail
Bone metastasis in Solid Tumor Market Expected to rise, 2034 | Mabwell Bioscience Co., Novartis, Institut Bergonié, Pfizer, GlaxoSmithKline, Amgen, QSAM Therapeutics, Actuate Therapeutics - Barchart
Earnings To Watch: Kirby (KEX) Reports Q4 Results Tomorrow - The Globe and Mail
Bone metastasis in Solid Tumor Market Expected to rise, 2034 | - openPR
TOROMONT TO ANNOUNCE 2024 FULL YEAR AND FOURTH QUARTER RESULTS ON FEBRUARY 11, 2025 - The Globe and Mail
Why IMAC Holdings Shares Are Trading Higher By Over 108%; Here Are 20 Stocks Moving Premarket - Benzinga
The Best High-Yield Energy Stock to Invest $200 in Right Now - The Globe and Mail
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
3 Artificial Intelligence (AI) Stocks That Could Go on a Multidecade Run - The Globe and Mail
Pre-market Movers: SAGE, ITCI, GCTK, MRNA... - RTTNews
EMA gives OMPD to Actuate’s pancreatic cancer therapy - MSN
Here's How Much Money You'd Have if You Invested $10,000 in Nvidia a Decade Ago - The Globe and Mail
Actuate Therapeutics (NASDAQ:ACTU) Shares Down 2.1%What's Next? - MarketBeat
EMA grants orphan drug designation to Actuate's cancer drug - Investing.com
Actuate Therapeutics Receives EMA Orphan Medicinal Product - GlobeNewswire
Actuate Therapeutics Receives EMA Orphan Medicinal Product Designation for Elraglusib for the Treatment of Pancreatic Cancer - Yahoo Finance
EMA grants orphan drug designation to Actuate's cancer drug By Investing.com - Investing.com South Africa
Elraglusib can prolong survival in metastatic pancreatic cancer: Trial - Myeloma Research News
Pancreatic Cancer Market Growth Projections 2024-2034: DelveInsight Analysis - EIN News
Actuate reports breakthrough in pancreatic cancer trial By Investing.com - Investing.com South Africa
Actuate sees 37% cut in risk of death in Phase II pancreatic cancer trial - Yahoo Finance
Actuate reports breakthrough in pancreatic cancer trial - Investing.com
Actuate Therapeutics Shares Rise 12% on Positive Phase 2 Trial to Treat Metastatic Pancreatic Ductal Cancer - MarketWatch
Actuate Therapeutics Announces Positive Interim Phase 2 - GlobeNewswire
Actuate's Pancreatic Cancer Drug Shows Breakthrough 44% One-Year Survival Rate in Phase 2 Trial - StockTitan
Actuate Therapeutics (NASDAQ:ACTU) Trading 0.8% HigherShould You Buy? - MarketBeat
Pre-market Movers: EWTX, TNXP, LNSR, VRDN... - RTTNews
Why RH Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket - Benzinga
Ewing Sarcoma Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Therapies, Patient Pool, Prevalence and Companies DelveInsight - The Globe and Mail
GXO Logistics: Time to Buy the Dip for the Rip in 2025 - The Globe and Mail
Actuate Therapeutics to be Added to Russell 2000® Index - The Manila Times
Actuate Therapeutics, oncology drug developer, sets terms for $50M IPO - MSN
Myelofibrosis Market to Show Remarkable Growth Trends from 2023 to 2032, DelveInsight Reports | Lynk Pharma, Samus Therapeutics, Taiga Biotech, Bristol-Myers Squibb, Sumitomo Pharma Oncology, Keros - Barchart
Palantir vs. Tesla: Which Growth Stock is a Better Buy Right Now? - The Globe and Mail
Mirdametinib Boosts Outcomes, QOL in NF1-PN - www.oncnursingnews.com/
FDA OKs Ninlotinib Tablets With No Mealtime Restrictions for CML - www.oncnursingnews.com/
FDA Grants Rare Pediatric Designation to Elraglusib for Ewing Sarcoma - www.oncnursingnews.com/
FDA grants rare disease status to Actuate's Ewing sarcoma drug By Investing.com - Investing.com Australia
FDA grants rare disease status to Actuate's Ewing sarcoma drug - Investing.com India
Actuate Therapeutics : FDA Grants Pediatric-Disease Status to Ewing Sarcoma Treatment - Marketscreener.com
Actuate Therapeutics: FDA Grants Pediatric-Disease Status to Ewing Sarcoma Treatment - MarketWatch
Actuate Announces FDA Rare Pediatric Disease Designation Granted to Elraglusib for Treatment of Ewing Sarcoma - The Manila Times
Elraglusib Earns FDA Rare Pediatric Disease Designation for Ewing Sarcoma - OncLive
Actuate Therapeutics (NASDAQ:ACTU) Stock Price Down 2.8%Time to Sell? - MarketBeat
Actuate to Participate in Lantern's Pharma Webinar on AI-Driven Drug Development - The Manila Times
Actuate to Participate in Lantern’s Pharma Webinar on AI-Driven Drug Development - GlobeNewswire
1.03%
자본화:
|
볼륨(24시간):